A Phase 3, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Chinese Population

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varenicline (Primary)
Indications Dry eyes
Focus Registrational; Therapeutic Use
Sponsors Ji Xing Pharmaceuticals

Most Recent Events

27 Oct 2024 According to a CORXEL media release, Ji Xing Pharmaceuticals name changed to CORXEL.
24 Apr 2023 Status changed from recruiting to completed.
11 Aug 2022 According to an Oyster Point Pharmaceuticals media release, this study may support a new drug application of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease in China.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight